Literature DB >> 10979954

Similar repopulating capacity of mitotically active and resting umbilical cord blood CD34(+) cells in NOD/SCID mice.

J Wilpshaar1, J H Falkenburg, X Tong, W A Noort, R Breese, D Heilman, H Kanhai, C M Orschell-Traycoff, E F Srour.   

Abstract

It was hypothesized that during mammalian development, the extensive need for hematopoietic cells requires equal contribution to blood cell production from both quiescent and cycling hematopoietic stem cells (HSCs) while maintaining the stem cell pool. To investigate this hypothesis, the engraftment potential of umbilical cord blood (UCB) CD34(+) cells residing in either G(0) (G(0)CD34(+) cells) or G(1) (G(1)CD34(+) cells) phases of the cell cycle was assessed in nonobese diabetic/severe combined immune-deficient (NOD/SCID) mice. Whereas the level of chimerism in mice transplanted with UCB G(0)CD34(+) cells was 69.9% +/- 24.0%, mice receiving equal numbers of G(1)CD34(+) cells harbored 46.7% +/- 21.3% human cells 8 weeks posttransplantation. Both groups of cells sustained multilineage differentiation and the production of CD34(+) cells in recipient animals. The relationship between the number of transplanted G(0)CD34(+) or G(1)CD34(+) cells and the level of chimerism was analyzed by a general linear models procedure. Although the initial level of chimerism following transplantation of G(0)CD34(+) cells was higher than that sustained by G(1)CD34(+) cells, the increment in the degree of chimerism obtained with each additional 10(3) cells of either phenotype was identical, suggesting that the reconstitution potential of these 2 types of cells was similar. Of interest is that human cells recovered from primary recipients of both G(0)CD34(+) and G(1)CD34(+) cells engrafted in secondary NOD/SCID recipients, albeit at a substantially lower level, confirming the primitive nature of UCB CD34(+) cells residing in G(1).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979954

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Stem cell research: State of the art.

Authors:  Sandro Eridani; Lidia Cova
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

2.  Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates.

Authors:  M Takatoku; S Sellers; B A Agricola; M E Metzger; I Kato; R E Donahue; C E Dunbar
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Expansion of human SCID-repopulating cells under hypoxic conditions.

Authors:  Guénahel H Danet; Yi Pan; Jennifer L Luongo; Dominique A Bonnet; M Celeste Simon
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

4.  Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials.

Authors:  Tulin Budak-Alpdogan; Isabelle Rivière
Journal:  Methods Mol Biol       Date:  2009

5.  Genomic and proteomic analysis of the impact of mitotic quiescence on the engraftment of human CD34+ cells.

Authors:  Brahmananda Reddy Chitteti; Yunlong Liu; Edward F Srour
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

6.  Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.

Authors:  Hal E Broxmeyer; Christie M Orschell; D Wade Clapp; Giao Hangoc; Scott Cooper; P Artur Plett; W Conrad Liles; Xiaxin Li; Barbara Graham-Evans; Timothy B Campbell; Gary Calandra; Gary Bridger; David C Dale; Edward F Srour
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

7.  Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state.

Authors:  Luca Trentin; Manon Queudeville; Sarah Mirjam Eckhoff; Nabiul Hasan; Vera Münch; Elena Boldrin; Felix Seyfried; Stefanie Enzenmüller; Klaus-Michael Debatin; Lüder Hinrich Meyer
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

8.  Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells.

Authors:  Michelle Millington; Allison Arndt; Maureen Boyd; Tanya Applegate; Sylvie Shen
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.